ÍøºìºÚÁÏ

Skip to main content

Paul L Crispen, MD : Research

Cancer Specialist (Oncologist), Urologist

Photo of Paul L Crispen

Research at a glance

Top areas of exploration

  • Kidney Neoplasms , 39 publications
  • Carcinoma, Renal Cell , 28 publications
  • Nephrectomy , 20 publications
  • Prostatic Neoplasms , 16 publications

Research activity

95 publications

4,527 citations

Why is this important?

Active clinical trials

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

Bladder cancer is the 8th most common cancer in the ÍøºìºÚÁÏ Cancer Center catchment area and the 7th most common cancer presenting to UFÍøºìºÚÁÏ. Most newly diagnosed cases are stage I bladder cancer, which is defined by having no deep muscle…

Investigator
Paul L Crispen
Status
Accepting Candidates
Ages
18 Years - N/A
Sexes
All

My publications

95 publications

2022

High Levels of PD-L1+ and Hyal2+ Myeloid-derived Suppressor Cells in Renal Cell Carcinoma.

Journal of kidney cancer and VHL

•

2022

Predicting Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.

Cancers

•

2022

Succinate dehydrogenase deficient renal cell carcinoma: A case report.

Urology case reports

•

2021

Association between nuclear grade of renal cell carcinoma and the aorta-lesion-attenuation-difference.

Abdominal radiology (New York)

•

2021

Hyal2 Expression in Tumor-Associated Myeloid Cells Mediates Cancer-Related Inflammation in Bladder Cancer.

Cancer research

•